Stocks · News reference

Canaccord Genuity Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $153

Jul 22, 2026, 11:12 AMBenzinga Newsdesk

Canaccord Genuity analyst Edward Nash initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $153.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 25, 2026, 12:34 PMBenzinga News-desk
Nektar Therapeutics Announces Publication Of Peer-Reviewed Data From 16-Week Induction Period Of REZOLVE-AD, Phase 2b Study Evaluating Rezpegaldesleukin In Adults With Atopic Dermatitis
REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2wFirst large, placebo-controlled trial to support T-reg modulation as
NKTR
BenzingaAug 21, 2026, 7:03 PMBenzinga Newsdesk
JP Morgan Reinstates Neutral on Nektar Therapeutics, Announces $65 Price Target
JP Morgan analyst Jessica Fye reinstates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and announces $65 price target.
NKTR
BenzingaAug 13, 2026, 10:20 PMBenzinga Insights
Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call
Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data
NKTR
SEC EDGARAug 13, 2026, 8:25 PMSEC EDGAR
8-K filing — NEKTAR THERAPEUTICS (NKTR)
Filed: 2026-08-13 AccNo: 0001213900-26-089137 Size: 292 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
NKTR